The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges

被引:40
作者
dos Santos, Rafael Guimaraes [1 ,2 ,3 ]
Carlos Bouso, Jose [1 ,3 ,4 ]
Rocha, Juliana Mendes [1 ]
Rossi, Giordano Novak [1 ]
Hallak, Jaime E. [1 ,2 ]
机构
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav, Ribeirao Preto, Brazil
[2] Natl Inst Sci & Technol Translat Med, Ribeirao Preto, Brazil
[3] ICEERS Fdn, Int Ctr Ethnobot Educ Res & Serv, Barcelona, Spain
[4] Univ Rovira & Virgili, Med Anthropol Res Ctr, Tarragona, Spain
基金
巴西圣保罗研究基金会;
关键词
hallucinogens; psychedelics; healthcare; LIFE-THREATENING CANCER; AYAHUASCA; PSILOCYBIN; DEPRESSION; ANXIETY; LSD; PSYCHEDELICS; PHARMACOLOGY; EXPERIENCES; SEROTONIN;
D O I
10.2147/RMHP.S300656
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Psychedelics or serotonergic hallucinogens are a group of substances that share the agonism of serotonergic 5-HT2A receptors as their main mechanism of action. Its main effects include changes in perception, cognitive process, and mood. Despite being used for centuries by different cultures in ritual contexts, these substances have currently aroused the interest of science and industry for their promising antidepressant, anxiolytic, and antiaddictive effects. Considering this evidence, this article aims to explore some of the possible health policy challenges to integrate these therapeutic tools into broad and heterogeneous health systems. As a main benefit, these substances produce rapid and enduring effects with the administration of single or few doses, which could lead to new treatment possibilities for patients with severe mental disorders resistant to the usual medications. The main challenge is associated with the fact that these substances remain scheduled in most countries and are associated with social stigma related to their recreational use (especially LSD and psilocybin). This situation makes it exceedingly difficult to conduct clinical trials, although international conventions allow such research. Ethically, this could be interpreted as a violation of human rights since thousands of people are prevented from having access to possible benefits. Interestingly, ritual ayahuasca use is more acceptable to the public than the use of psilocybin-containing mushrooms or LSD. The controlled, clinical use of LSD and psilocybin seems to be less criticized and is being explored by the industry. Rigorous scientific evidence coupled with industrial interests (LSD and psilocybin), together with respect for traditional uses (ayahuasca) and international conventions, seems to be the best way for these drugs to be integrated into health systems in the next years. Which highlights the need for an urgent dialogue between science, health system, society, and politics.
引用
收藏
页码:901 / 910
页数:10
相关论文
共 84 条
[1]   Psychedelics and Personality [J].
Aixala, Marc ;
dos Santos, Rafael G. ;
Hallak, Jaime E. C. ;
Carlos Bouso, Jose .
ACS CHEMICAL NEUROSCIENCE, 2018, 9 (10) :2304-2306
[2]  
[Anonymous], GLOBAL PSYCHEDELIC T
[3]   N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function [J].
Barker, Steven A. .
FRONTIERS IN NEUROSCIENCE, 2018, 12
[4]  
Bauer BarbaraE., 2019, Psychedelic Science Review
[5]  
Berlowitz I, 2020, J STUD ALCOHOL DRUGS, V81, P416
[6]   Antidepressant effects of ketamine in depressed patients [J].
Berman, RM ;
Cappiello, A ;
Anand, A ;
Oren, DA ;
Heninger, GR ;
Charney, DS ;
Krystal, JH .
BIOLOGICAL PSYCHIATRY, 2000, 47 (04) :351-354
[7]  
Bogenschutz MP, 2018, CURR TOP BEHAV NEURO, V36, P361, DOI 10.1007/7854_2016_464
[8]   Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study [J].
Bogenschutz, Michael P. ;
Forcehimes, Alyssa A. ;
Pommy, Jessica A. ;
Wilcox, Claire E. ;
Barbosa, P. C. R. ;
Strassman, Rick J. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2015, 29 (03) :289-299
[9]   Regulation of human research with LSD in the United States (1949-1987) [J].
Bonson, Katherine R. .
PSYCHOPHARMACOLOGY, 2018, 235 (02) :591-604
[10]   Serotonin and brain function: a tale of two receptors [J].
Carhart-Harris, R. L. ;
Nutt, D. J. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2017, 31 (09) :1091-1120